Prenetics has shelved its Bitcoin treasury initiative less than three months after securing a $48 million funding round explicitly earmarked for crypto accumulation, pivoting instead toward its explosively performing IM8 supplement brand—a strategic about-face that raises the inevitable question of whether the company ever truly committed to the cryptocurrency holdings strategy it so publicly championed just six months prior.
Prenetics abandons Bitcoin accumulation barely three months after securing $48M in crypto-focused funding, pivoting dramatically toward its surging IM8 supplement brand.
The Nasdaq-listed firm, which announced its Bitcoin acquisition program in June as healthcare’s first entrant into the digital asset treasury space, formally ceased daily purchases on December 4 following board approval, though it retains 510 Bitcoin valued near $45 million as a reserve asset.
The reversal stems from IM8’s staggering performance metrics. The David Beckham-backed consumer health brand generated $17.2 million in Q3 2025—a 76% sequential jump—and has already accumulated over $100 million in annualized recurring revenue just eleven months post-launch, positioning itself as potentially the fastest-growing supplement brand in industry history.
Management projects $180-200 million in fiscal 2026 revenue, figures that dwarf the company’s broader operations and apparently justify redirecting all capital toward product innovation, international expansion, and talent acquisition rather than accumulating digital assets at $88,524 per Bitcoin.
The timing, however, invites skepticism. Bitcoin’s recent stumble below $100,000 and the broader softening of institutional crypto adoption narratives clearly influenced the decision, even as company statements emphasize IM8’s organic success.
The regulatory landscape surrounding cryptocurrency treasury strategies has also grown increasingly complex, with companies navigating evolving Basel Committee guidelines that address institutional exposure to digital assets.
Prenetics investors—including crypto-native firms like Kraken, Exodus, and GPTX—funded what appeared to be a serious treasury strategy modeled on MicroStrategy’s Michael Saylor playbook. Instead, they received a spectacular supply-side pivot within weeks.
The stock fell 3.3% on announcement day despite the company’s 189% year-to-date gain and positioning atop a $70 million cash fortress alongside zero debt.
Whether this reversal signals tactical pragmatism or strategic whiplash remains contested; what’s indisputable is that Prenetics has elected growth concentration over diversification, betting the David Beckham brand extension—not blockchain—represents the generation-defining opportunity worthy of institutional capital.
